File Name: cancer chemotherapy and pharmacology .zip
There are many chemotherapy drugs, and often several are given together. Depending on the type of cancer, its size, and whether it has spread, chemotherapy may cure the cancer, slow or prevent its spread, or make its symptoms better.
Use the A to Z list below to find consumer-friendly information about drugs for cancer and conditions related to cancer. The list is in alphabetical order by generic name and brand name. You can also find this information on our pages organized by cancer type and cancer-related condition:. This page lists and links to NCI's pages of drugs approved for specific types of cancer in adults and children.
If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus. Please consult the latest official manual style if you have any questions regarding the format accuracy.
Cancer chemotherapy remains an intriguing area of pharmacology. On the other hand, some types of cancer are barely affected by currently available drugs. Furthermore, as a group, the anticancer drugs are more toxic than any other pharmaceutic agents, and thus their benefit must be carefully weighed against their risks. Many of the available drugs are cytotoxic agents that act on all dividing cells, cancerous or normal.
The ultimate goal in cancer chemotherapy is to use advances in cell biology to develop drugs that selectively target specific cancer cells. A few such agents are in clinical use, and many more are in development. Cancer cell population kinetics and the cancer cell cycle are important determinants of the actions and clinical uses of anticancer drugs.
Some anticancer drugs exert their actions selectively on cycling cells cell cycle-specific [CCS] drugs , and others cell cycle-nonspecific [CCNS] drugs kill tumor cells in both cycling and resting phases of the cell cycle although cycling cells are more sensitive. CCS drugs are usually most effective when cells are in a specific phase of the cell cycle Figure 54—1.
Both types of drugs are most effective when a large proportion of the tumor cells are proliferating ie, when the growth fraction is high.
Phases of the cell cycle that are susceptible to the actions of cell cycle-specific CCS drugs. All dividing cells—normal and neoplastic—must traverse these cell cycle phases before and during cell division. Tumor cells are usually most responsive to specific drugs or drug groups in the phases indicated. Cell cycle-nonspecific CCNS drugs act on tumor cells while they are actively cycling and while they are in the resting phase G 0.
McGraw-Hill, Fig. Cytotoxic drugs act with first-order kinetics in a murine model of leukemia. In this model system, in which all the cells are actively progressing through the cell cycle, a given dose kills a constant proportion of a cell population rather than a constant number of cells. The log-kill hypothesis proposes that the magnitude of tumor cell kill by anticancer drugs is a logarithmic function. Forgot Password? Otherwise it is hidden from view. Forgot Username?
About MyAccess If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Learn More. Sign in via OpenAthens. Sign in via Shibboleth. AccessBiomedical Science. AccessEmergency Medicine. Case Files Collection. Clinical Sports Medicine Collection. Davis AT Collection. Davis PT Collection. Murtagh Collection. About Search. Enable Autosuggest. You have successfully created a MyAccess Profile for alertsuccessName. Previous Chapter. Next Chapter.
Trevor A. Anthony J. Trevor, et al. McGraw-Hill; Accessed March 07, APA Citation Cancer chemotherapy. Download citation file: RIS Zotero. Reference Manager. Search Textbook Autosuggest Results.
If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus. Please consult the latest official manual style if you have any questions regarding the format accuracy. Cancer chemotherapy remains an intriguing area of pharmacology. On the one hand, use of anticancer drugs produces high rates of cure of diseases, which, without chemotherapy, result in extremely high mortality rates eg, acute lymphocytic leukemia in children, testicular cancer, and Hodgkin's lymphoma. On the other hand, some types of cancer are barely affected by currently available drugs. Furthermore, as a group, the anticancer drugs are more toxic than any other pharmaceutic agents, and thus their benefit must be carefully weighed against their risks. Many of the available drugs are cytotoxic agents that act on all dividing cells, cancerous or normal.
Cancer Chemotherapy and Pharmacology is a peer-reviewed medical journal covering oncological pharmacotherapy. The editors-in-chief are E. Chatelut Paul Sabatier University and E. Sausville University of Maryland. This article about a scientific journal on pharmacology is a stub.
Populations around the world are aging, and the associated increase in cancer incidence has led to the recognition of the importance of geriatric oncology. Chronological age is a poor determinant of pharmacological response to cancer chemotherapy agents. Age-associated changes in physiology and organ function have a significant impact on the clinical pharmacology of cancer chemotherapy agents used in cancer treatment. Altered response to medicines in older people is a consequence of changes in body composition, organ function, concomitant pathophysiology, multiple medications, genetic determinants of drug response, and patient's clinical status. These issues highlight the need to individualize the management of cancer in the older people with consideration of age-related changes in the clinical pharmacology of cancer drugs, analgesics, and adjunctive therapies.
The side-effects and long-term sequelae of anti-cancer chemotherapy remain a major source of concern for both patients and clinicians despite the improved efficacy and enhanced survival offered by modern treatments. Current drugs or other approaches to counteract chemotherapy-induced adverse effects are often incompletely effective, frequently do not address potential longer-term sequelae or may even induce other side-effects which only add to patient discomfort. New approaches to improve tolerance and reduce sequelae of cancer chemotherapy are urgently needed and the present Research Topic focuses on this issue and highlights several areas of progress.
Your email address will not be published. Required fields are marked *